Therapeutic Focus

Atopic Dermatitis associated Pruritus (AD-aP)

Novel Therapy for Atopic Dermatitis associated Pruritus

Cara Therapeutics is developing a novel therapy to change the way pruritus (itch) associated with AD is managed. Cara is developing a completely new class of medicine called kappa opioid receptor agonists. Kappa agonists target a completely different receptor in the body, the kappa receptor, to treat itch in a new way. Our lead pipeline product, KORSUVA (difelikefalin) is a peripherally acting kappa agonist. To date, we are studying KORSUVA Tablets in a Phase 2 trial for patients with AD.